Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma

Human Pathology

Volumn 44, Issue 10, 2013, Pages 2266-2274

  Reis, Henning ^a   Hager, Thomas ^a   Wohlschlaeger, Jeremias ^a   Bauer, Sebastian ^a   Katenkamp, Kathrin ^b   Katenkamp, Detlef ^b   Baba, Hideo Andreas ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Alveolar soft part sarcoma; ASPS; mTOR; Rapamycin; Targeted therapy

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN KINASE B; PROTEIN KINASE B PHOSPHORYLATED AT THREONINE 308; S6 KINASE; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOR IMMUNOGLOBULIN HEAVY CHAIN ENHANCER 3; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALVEOLAR SOFT PART SARCOMA; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; TUMOR GROWTH;

(P)ERK; (PHOSPHORYLATED) EXTRACELLULAR SIGNAL-REGULATED KINASES; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1; ALVEOLAR SOFT PART SARCOMA; ASPL-TFE3; ASPS; CMET; FFPE; FISH; FLUORESCENCE IN SITU HYBRIDIZATION; FORMALIN-FIXED AND PARAFFIN-EMBEDDED TISSUE; FUSION PROTEIN OF THE TRANSLOCATION OF THE ALVEOLAR SOFT PART SARCOMA CRITICAL REGION-1 AND THE TRANSCRIPTION FACTOR FOR IMMUNOGLOBULIN HEAVY-CHAIN ENHANCER 3 GENES; GENE ENCODING THE HEPATOCYTE GROWTH FACTOR RECEPTOR PROTEIN; IMMUNOREACTIVE SCORE; IRS; LEIOMYOSARCOMA; LIPOSARCOMA; LMS; LS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MEK; MICROPHTHALMIA TRANSCRIPTION FACTOR; MITF; MITOGEN-ACTIVATED PROTEIN KINASE KINASE; MTOR; MTORC1; MTORC2; P4EBP1; PAKT S473; PAKT T308; PDK1; PHOSPHATIDYLINOSITIDE 3-KINASES; PHOSPHORYLATED 4E-BINDING PROTEIN 1; PHOSPHORYLATED P70-S6 KINASE 1; PI3K; PP70S6K; PROTEIN KINASE B PHOSPHORYLATED AT SERINE 473; PROTEIN KINASE B PHOSPHORYLATED AT THREONINE 308; RAF; RAPAMYCIN; RAS; RAT FIBROSARCOMA PROTEIN FAMILY; RAT SARCOMA PROTEIN FAMILY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RT-PCR; SYNOVIAL SARCOMA; SYS; TARGETED THERAPY; TFE3; TRANSCRIPTION FACTOR FOR IMMUNOGLOBULIN HEAVY-CHAIN ENHANCER 3; TSC1/TSC2; TUBEROUS SCLEROSIS PROTEIN 1/TUBEROUS SCLEROSIS PROTEIN 2 COMPLEX; UNDIFFERENTIATED PLEOMORPHIC SARCOMA; UPS;

ADOLESCENT; ADULT; AGED; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, ALVEOLAR SOFT PART; SARCOMA, SYNOVIAL; SIGNAL TRANSDUCTION; SOFT TISSUE NEOPLASMS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84884419328     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.04.018     Document Type: Article

References (34)

1. S.W. Weiss, and J.R. Goldblum Alveolar soft part sarcoma S.W. Weiss, J.R. Goldblum, Soft tissue tumors 5th Ed. 2008 Mosby Elsevier Maryland Heights, USA 1182 1191
2. P.H. Lieberman, M.F. Brennan, M. Kimmel, R.A. Erlandson, P. Garin-Chesa, and B.Y. Flehinger Alveolar soft-part sarcoma. A clinico-pathologic study of half a century Cancer 63 1989 1 13
3. C.A. Portera Jr., V. Ho, and S.R. Patel Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution Cancer 91 2001 585 591
4. S. Stacchiotti, E. Tamborini, and A. Marrari Response to sunitinib malate in advanced alveolar soft part sarcoma Clin Cancer Res 15 2009 1096 1104
5. B. Mitton, and N. Federman Alveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapies Sarcoma 2012 2012 428 789
6. A.J. Wagner, J.M. Goldberg, and S.G. Dubois Tivantinib (ARQ 197), a selective inhibitor of mesenchymal-epithelial transition factor, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial Cancer 118 2012 5894 5902
7. A.A. Azizi, C. Haberler, and T. Czech Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma Lancet Oncol 7 2006 521 523
8. Keryx/AOI Pharmaceuticals, Inc. A trial of perifosine in patients with chemo-insensitive sarcomas, 2012, clinicaltrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT00401388. Accessed January 10, 2013.
9. D.T. Vistica, M. Hollingshead, and S.D. Borgel Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy J Pediatr Hematol Oncol 31 2009 561 570
10. M. Ladanyi, M.Y. Lui, and C.R. Antonescu The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 Oncogene 20 2001 48 57
11. B.C. Dickson, J.S. Brooks, T.L. Pasha, and P.J. Zhang TFE3 expression in tumors of the microphthalmia-associated transcription factor (MiTF) family Int J Surg Pathol 19 2011 26 30
12. G. Alexandru, J. Graumann, G.T. Smith, N.J. Kolawa, R. Fang, and R.J. Deshaies UBXD7 binds multiple ubiquitin ligases and implicates p97 in HIF1alpha turnover Cell 134 2008 804 816
13. M. Tsuda, I.J. Davis, and P. Argani TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition Cancer Res 67 2007 919 929
14. K.G. Foster, and D.C. Fingar Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony J Biol Chem 285 2010 14071 14077
15. L. Willems, J. Tamburini, N. Chapuis, C. Lacombe, P. Mayeux, and D. Bouscary PI3K and mTOR signaling pathways in cancer: new data on targeted therapies Curr Oncol Rep 14 2012 129 138
16. J.E. Dancey Therapeutic targets: MTOR and related pathways Cancer Biol Ther 5 2006 1065 1073
17. G. Procopio, E. Verzoni, R. Iacovelli, V. Guadalupi, F. Gelsomino, and R. Buzzoni Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience Expert Rev Anticancer Ther 11 11 2011 1631 1640
18. M. Agulnik New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma Cancer 118 2012 1486 1497
19. C.D.M. Fletcher, A. Rydholm, S. Singer, M. Sundaram, and J.M. Coindre Soft tissue tumours: epidemiology, clinical features, histopathological typing and grading C.M.D. Fletcher, K.K. Unni, F. Mertens, World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone 2002 IARC Press Lyon, France 12 18
20. M. Zhong, P. De Angelo, and L. Osborne Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma Am J Surg Pathol 34 2010 757 766
21. S. Aulmann, T. Longerich, P. Schirmacher, G. Mechtersheimer, and R. Penzel Detection of the ASPSCR1-TFE3 gene fusion in paraffin-embedded alveolar soft part sarcomas Histopathology 50 2007 881 886
22. S. Stacchiotti, T. Negri, and N. Zaffaroni Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect Ann Oncol 22 2011 1682 1690
23. A. Valkov, T.K. Kilvaer, S.W. Sorbye, T. Donnem, E. Smeland, R.M. Bremnes, and L.T. Busund The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas J Transl Med 9 2011 200
24. E. Jacinto, V. Facchinetti, and D. Liu SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity Cell 127 2006 125 137
25. A.J. Lazar, G. Lahat, and S.E. Myers Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray Histopathology 55 2009 750 755
26. Y. Tomita, T. Morooka, and Y. Hoshida Prognostic significance of activated AKT expression in soft-tissue sarcoma Clin Cancer Res 12 2006 3070 3077
27. P. Argani, P. Lal, B. Hutchinson, M.Y. Lui, V.E. Reuter, and M. Ladanyi Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay Am J Surg Pathol 27 2003 750 761
28. A. Williams, G. Bartle, V.P. Sumathi, J.M. Meis, D.C. Mangham, R.J. Grimer, and L.G. Kindblom Detection of ASPL/TFE3 fusion transcripts and the TFE3 antigen in formalin-fixed, paraffin-embedded tissue in a series of 18 cases of alveolar soft part sarcoma: useful diagnostic tools in cases with unusual histological features Virchows Arch 458 2011 291 300
29. B. Rekhi, A. Ingle, M. Agarwal, A. Puri, S. Laskar, and N.A. Jambhekar Alveolar soft part sarcoma 'revisited': clinicopathological review of 47 cases from a tertiary cancer referral centre, including immunohistochemical expression of TFE3 in 22 cases and 21 other tumours Pathology 44 2012 11 17
30. S. Macher-Goeppinger, W. Roth, and N. Wagener Molecular heterogeneity of TFE3 activation in renal cell carcinomas Mod Pathol 25 2 2012 308 315
31. M.A. Dickson, G.K. Schwartz, C.R. Antonescu, D.J. Kwiatkowski, and I.A. Malinowska Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates Int J Cancer 132 2013 1711 1717
32. A. Astrinidis, and E.P. Henske Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease Oncogene 24 2005 7475 7481
33. X. Wan, B. Harkavy, N. Shen, P. Grohar, and L.J. Helman Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism Oncogene 26 2007 1932 1940
34. R.J. Shaw, and L.C. Cantley Ras, PI(3)K and mTOR signalling controls tumour cell growth Nature 441 2006 424 430